For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Novmetapharma Co., Ltd.

USPTO Granted Patents = 14

EPO Patents = 9

Forward Citations = 8

Loading Chart...

Loading Chart...

31 inventors (with patents filed for the assignee):

Heon Jong Lee (6 out of 6 patents)

Hoe Yune Jung (6 out of 6 patents)

Hoe-Yune Jung (5 out of 5 patents)

4. Heon-Jong Lee (3 out of 3 patents)

5. Jong-Su Jeon (3 out of 3 patents)

6. Yon-Su Kim (3 out of 3 patents)

7. Seung-Hee Yang (3 out of 3 patents)

8. Yong-Chul Kim (3 out of 26 patents)

9. Jong-Joo Moon (3 out of 3 patents)

10. Hwan-Soo Yoo (3 out of 3 patents)

11. Kyeong-Mi Choi (3 out of 3 patents)

12. Do Hyun Lee (3 out of 3 patents)

13. In-Kyu Lee (2 out of 5 patents)

14. Jae-Han Jeon (2 out of 5 patents)

15. Kay Olmstead (2 out of 16 patents)

14 patents: Sort by Forward Citations

1. 12053467 - Method of treating fibrosis (2024-08-06),

2. 11975041 - Composition comprising CHP (cyclo-his pro) for preventing, improving or treating of bone loss related disease (2024-05-07),

3. 11890317 - Cell-protecting composition containing cyclo histidine-proline as active ingredient (2024-02-06),

4. 11850246 - Method for treatment of cytokine release syndrome (2023-12-26),

5. 11820834 - Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease (2023-11-21),

6. 11607441 - Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients (2023-03-21),

7. 11547737 - Compositions and methods for treating virus infection (2023-01-10),

8. 11433114 - Composition for cell protection containing cyclo histidine-proline as active ingredient (2022-09-06),

9. 11413270 - Method for the treatment of pancreatitis (2022-08-16),

10. 11273196 - Antithrombotic composition containingand (2022-03-15),

11. 10918693 - Composition for cell protection containing cyclo histidine-proline as active ingredient (2021-02-16),

12. 10792280 - Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes (2020-10-06),

13. 10683300 - Polymorphic forms of Cyclo (-His-Pro) (2020-06-16),

14. 10004727 - Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient (2018-06-26),

Novmetapharma Co., Ltd. is a leading pharmaceutical company specializing in the development and manufacture of innovative medicines. With a focus on research and development, Novmetapharma aims to improve the quality of life for patients worldwide. The company's diverse product portfolio includes treatments for a wide range of medical conditions, from chronic diseases to rare disorders. Committed to excellence in healthcare, Novmetapharma continues to drive innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

14 Patents

#248 in Seoul

#777 in South Korea

#40,933 in the World

Seoul, South Korea

Novmetapharma Co., Ltd.

Forward Citations = 8

31 inventors:

Heon Jong Lee (6 out of 6 patents)

Hoe Yune Jung (6 out of 6 patents)

Hoe-Yune Jung (5 out of 5 patents)

4. Heon-Jong Lee (3 out of 3 patents)

5. Jong-Su Jeon (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…